A heterologous booster vaccination strategy against Covid-19 can be considered - for logistical reasons and in some cases for more effective protection - according to the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC).
In a report published on Tuesday 7 December, the two institutions state that the data available to date has allowed them to conclude that a booster given with a different vaccine from the one used in the primary vaccination...